Synthesis of an18F-fluorobenzoate idarubicin derivative as new potential PET radiotracer to predict chemotherapy resistance

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 48, Issue 11, 2005, Pages 819-827

  Seimbille, Yann ^a   Czernin, Johannes ^a   Phelps, Michael E ^a   Silverman, Daniel H S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anthracyclines; Chemotherapy; Fluorine 18; Positron emission tomography

Indexed keywords

BYPRODUCTS; CHEMOTHERAPY; FLUORINE; FLUORINE COMPOUNDS; POSITRON EMISSION TOMOGRAPHY;

'CURRENT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTITUMOUR AGENTS; ASSAY SYSTEM; CHEMORESISTANCE; CLINICAL PRACTICES; FLUORINE-18; IN-VIVO; SYNTHETIC PATHWAYS;

TUMORS;

9 ACETYL 7 [[3 [(4 FLUOROBENZOYL)AMINO] 2,3,6 TRIDEOXY ALPHA LEVO LYXO HEXOPYRANOSYL]OXY] 7,8,9,10 TETRAHYDRO 6,9,11 TRIHYDROXY 5,12 NAPHTHACENEDIONE; ANTHRACYCLINE; BENZOIC ACID DERIVATIVE; FLUORINE 18; FLUOROBENZOIC ACID; IDARUBICIN; IDARUBICIN DERIVATIVE; TRACER; UNCLASSIFIED DRUG;

ACYLATION; ARTICLE; CHEMOTHERAPY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; POSITRON EMISSION TOMOGRAPHY; RADIOCHEMISTRY;

EID: 27544471844     PISSN: 03624803     EISSN: None     Source Type: Journal    
DOI: 10.1002/jlcr.990     Document Type: Article

References (19)

1. Silverman DH, Hoh CK, Seltzer MA, Schiepers C, Cuan GS, Gambhir SS, Zheng L, Czernin J, Phelps ME. Semin Radiat Oncol 1998; 8: 183-196.
2. Gupta N, Price PM, Aboagye EO. Eur J Cancer 2002; 38: 2094-2107.
3. Hutchinson OC, Collingridge DR, Barthel H, Price PM, Aboagye EO. Curr Pharm Des 2003; 9: 917-929.
4. Aboagye EO, Price PM. Invest New Drugs 2003; 21: 169-181.
5. Dimitrakopoulou A, Strauss LG, Clorius JH, Ostertag H, Schlag P, Heim M, Oberdorfer F, Helus F, Haberkorn U, Vankaick G. J Nucl Med 1993; 34: 1075-1081.
6. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Mohler M, Oberdorfer F, et al. J Nucl Med 1998; 39: 1197-1202.
7. Moehler M, Dimitrakopoulou-Strauss A, Gutzler F, Raeth U, Strauss LG, Stremmel W. Cancer 1998; 83: 245-253.
8. Meikle SR, Matthews JC, Brock CS, Wells P, Harte RJ, Cunningham VJ, Jones T, Price P. Cancer Chemother Pharmacol 1998; 42: 183-193.
9. Kesner AL, Lacan G, Gangloff A, Zheng L, Czernin J, Melega WP, Silverman DH. J Nucl Med 2003; 44: 297.
10. Gangloff A, Kesner AL, Hsueh WA, Kiesewetter DO, Eckelman W, Czernin J, Pegram M, Beryt M, Silverman DH. J Nucl Med 2003; 44: 374.
11. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Pharmacol Rev 2004; 56: 185-229.
12. Moro S, Beretta GL, Dal Ben D, Nitiss J, Palumbo M, Capranico G. Biochemistry 2004; 43: 7503-7513.
13. Elsinga PH, Franssen EJF, Vandergraaf WTA, Devries EGE, Visser GM, Vaalburg W. J Nucl Med 1994; 35: 83.
14. Elsinga PH, Franssen EJF, Hendrikse NH, Fluks L, Weemaes AMA, vanderGraaf WTA, de Vries GE, Visser GM, Vaalburg W. J Nucl Med 1996; 37: 1571-1575.
15. Elsinga PH, Hendrikse NH, Bart J, Vaalburg W, van Waarde A. Curr Pharm Des 2004; 10: 1493-1503.
16. Hadfield JA, Pietrzynski G, Bailey J, Alakhov V, Sosabowski JK, Zweit J, Ranson M. J Label Compd Radiopharm 2001; 44: S370-S371.
17. Hamblett I, Gillies J, Hadfield JA, Bailey J, Ranson M, Zweit J. J Label Compd Radiopharm 2003; 46: S130.
18. Kiesewetter DO, Jagoda EM, Kao CH, Ma Y, Ravasi L, Shimoji K, Szajek LP, Eckelman WC. Nucl Med Biol 2003; 30: 11-24.
19. Lang LX, Jagoda E, Schmall B, Vuong BK, Adams HR, Nelson DL, Carson RE, Eckelman WC. J Med Chem 1999; 42: 1576-1586.